Part II: Testicular cancer—management of advanced disease
- 1 December 2003
- journal article
- Published by Elsevier in The Lancet Oncology
- Vol. 4 (12), 738-747
- https://doi.org/10.1016/s1470-2045(03)01279-8
Abstract
No abstract availableKeywords
This publication has 56 references indexed in Scilit:
- The role of adjunctive postchemotherapy surgery for nonseminomatous germ-cell tumors: Current concepts and controversiesSeminars in Urologic Oncology, 2002
- Irinotecan plus cisplatin has substantial antitumor effect as salvage chemotherapy against germ cell tumorsCancer, 2002
- Absence of c‐KIT and members of the epidermal growth factor receptor family in refractory germ cell cancerCancer, 2002
- Radiotherapy after chemotherapy for metastatic seminoma—a diminishing roleEuropean Journal Of Cancer, 1997
- Clinical stage B non-seminomatous germ cell testis cancer: The Indiana University experience (1965–1989) using routine primary retroperitoneal lymph node dissectionEuropean Journal Of Cancer, 1995
- Original Articles: Testis Cancer: Complications of Post-Chemotherapy Retroperitoneal Lymph Node DissectionJournal of Urology, 1995
- Early salvage therapy for germ cell cancer using high dose chemotherapy with autologous bone marrow supportCancer, 1994
- Phase II Trial of High-Dose Carboplatin and Etoposide With Autologous Bone Marrow Transplantation in First-Line Therapy for Patients With Poor-Risk Germ Cell TumorsJNCI Journal of the National Cancer Institute, 1993
- Treatment of Disseminated Germ-Cell Tumors with Cisplatin, Bleomycin, and either Vinblastine or EtoposideNew England Journal of Medicine, 1987
- The Role of Maintenance Therapy in Disseminated Testicular CancerNew England Journal of Medicine, 1981